Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;18(7-8):360-4.
doi: 10.1007/BF03091792.

TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives

M W Z Basalus  1 , K Tandjung, K G van Houwelingen, M G Stoel, F H A F de Man, J W Louwerenburg, S A M Saïd, G C M Linssen, M A W J Kleijne, J van der Palen, J Huisman, P M J Verhorst, C von Birgelen
Affiliations

TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives

M W Z Basalus et al. Neth Heart J. 2010 Aug.

Abstract

Background. New-generation drug-eluting stents (DES) may solve several problems encountered with first-generation DES, but there is a lack of prospective head-to-head comparisons between new-generation DES. In addition, the outcome of regulatory trials may not perfectly reflect the outcome in 'real world' patients.Objectives. To compare the efficacy and safety of two new-generation DES in a 'real world' patient population.Methods. A prospective, randomised, single-blinded clinical trial to evaluate clinical outcome after Endeavor Resolute vs. Xience V stent implantation. The primary endpoint is target vessel failure at one-year follow-up. In addition, the study comprises a two-year and an open-label five-year follow-up. (Neth Heart J 2010;18:360-4.).

Keywords: Drug-Eluting Stents; Angioplasty, Transliminal, Percutaneous Coronary; Coronary Artery Diseases; Randomized Controlled Trial; Thrombosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Geometry and surface morphology of Endeavor Resolute and Xience V. Micro-computed tomography images of Endeavor Resolute (A) and Xience V (B). Scanning electron microscopic images of Endeavor Resolute (C) and Xience V (D) (images from ongoing bench side studies in DES, performed by C. von Birgelen and co-workers, University of Twente, Enschede, the Netherlands.
See this image and copyright information in PMC

References

    1. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2006;27:260-6. - PubMed
    1. Vermeersch P, Agostoni P, Verheye S, Van den HP, Convens C, Bruining N, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48:2423-31. - PubMed
    1. Briguori C, Colombo A, Airoldi F, Focaccio A, Iakovou I, Chieffo A, et al. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Am Heart J. 2005;150:807-13. - PubMed
    1. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48. - PubMed
    1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-206. - PubMed

LinkOut - more resources